Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genprex, Inc. - Common Stock (NQ:GNPX)

0.7715 -0.0496 (-6.04%)
Streaming Delayed Price Updated: 12:01 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program
Via Investor Brand Network
Topics Intellectual Property
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’
Via Investor Brand Network
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Important Clinical Programs Forward
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for Patients with SCLC
Via Investor Brand Network
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning! 
Via InvestorPlace
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offering
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering
Via Investor Brand Network
News headline image
Why Amarin Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) rose 43% to $6.91. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh
Via Investor Brand Network
Topics Intellectual Property
News headline image
Genprex – FDA Grants Fast Track Approval For Promising New Cancer Gene Therapy ↗
Rodney Varner, CEO, Chairman & President of Genprex, Inc. (NASDAQ: GNPX), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline
Via Investor Brand Network
News headline image
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
News headline image
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast
Via Investor Brand Network
Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination in Many of the Largest Markets
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives Fast Track Designation for Proprietary Immunogene Therapy
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.